The estimated Net Worth of Raymond W Cohen is at least $55.8 Milion dollars as of 24 July 2024. Mr. Cohen owns over 103,896 units of Axonics Inc stock worth over $20,119,402 and over the last 21 years he sold AXNX stock worth over $29,575,622. In addition, he makes $6,147,640 as Chief Executive Officer i Director at Axonics Inc.
Raymond has made over 37 trades of the Axonics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 103,896 units of AXNX stock worth $2,383,374 on 24 July 2024.
The largest trade he's ever made was exercising 103,896 units of Axonics Inc stock on 24 July 2024 worth over $2,383,374. On average, Raymond trades about 16,698 units every 54 days since 2004. As of 24 July 2024 he still owns at least 292,731 units of Axonics Inc stock.
You can see the complete history of Mr. Cohen stock trades at the bottom of the page.
Raymond Wayne Cohen serves as Chief Executive Officer, Director of the Company. Mr. Cohen has extensive medical device experience, holding several Chair and Chief Executive Officer positions on the boards of publicly listed life sciences companies. Mr. Cohen is an accredited public company director having completed the UCLA certification program for public company directors. Since May 2006, Mr. Cohen has served as a member of the board of directors, Chair of the audit committee, compensation committee and nominating committee, and since November 2013 as Chair of the board of directors, of BioLife Solutions, Inc., (NASDAQ: BLFS), a developer, manufacturer and supplier of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media for human cells. From June 2013 to April 2020, Mr. Cohen served as a member of the board of directors, Chair of the compensation committee, member of the audit committee and member of the nominating and corporate governance committee of Spectrum Pharmaceuticals, Inc., (NASDAQ: SPPI), a developer and marketer of oncology and hematology drugs. From April 2016 to June 2017, Mr. Cohen served as a member of the board of directors and a member of the compensation and audit committees of publicly listed Zurich-based LifeWatch AG, a manufacturer and marketer of ambulatory electrocardiogram services, which was acquired by Biotelemetry Inc. (NASDAQ: BEAT), in July 2017. From June 2013 to December 2017, Mr. Cohen served as Chair of the board of directors of Lombard Medical, Inc., a manufacturer and marketer of abdominal aortic aneurysm stent graphs. From August 2010 to November 2012, Mr. Cohen served as Chief Executive Officer and as a member of the board of directors of Vessix Vascular, Inc., a developer of a novel renal denervation system used to treat uncontrolled hypertension, which was acquired by Boston Scientific Corporation. From 1997 to 2006,
As the Chief Executive Officer i Director of Axonics Inc, the total compensation of Raymond Cohen at Axonics Inc is $6,147,640. There are no executives at Axonics Inc getting paid more.
Raymond Cohen is 61, he's been the Chief Executive Officer i Director of Axonics Inc since 2015. There are 4 older and 18 younger executives at Axonics Inc. The oldest executive at Axonics Inc is Nancy Snyderman, 68, who is the Independent Director.
Raymond's mailing address filed with the SEC is 26, Technology Drive, Irvine Spectrum, Irvine, Orange County, California, 92618, United States.
Over the last 6 years, insiders at Axonics Inc have traded over $108,010,643 worth of Axonics Inc stock and bought 4,672,163 units worth $70,180,620 . The most active insiders traders include Asset Management, Lp Chen B..., Shahzad Malik oraz Geoff Pardo. On average, Axonics Inc executives and independent directors trade stock every 15 days with the average trade being worth of $4,280,711. The most recent stock trade was executed by Raymond W Cohen on 24 July 2024, trading 103,896 units of AXNX stock currently worth $2,383,374.
axonics modulation technologies, inc is a privately-held medical device company developing an innovative neuromodulation platform based on a miniaturized rechargeable fully-implantable ipg licensed from the alfred mann foundation. the axonics sacral neuromodulation system is designed to improve the experience of both clinicians and patients suffering from urinary and fecal dysfunction.
Axonics Inc executives and other stock owners filed with the SEC include: